MaxCyte, Inc. (MXCT)
Nasdaq · Healthcare · Medical Devices
$1.08+0.93%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $112M
- 52-week range
- $0.643 – $1.87
- 52-week change
- −30.97%
- EPS (trailing)
- −$0.34
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $33.0M (−14.50%)
- Net income
- −$44.6M
- Operating margin
- −157.1%
- Diluted EPS
- −$0.42
- Free cash flow
- −$36.2M
From the company’s annual report on SEC EDGAR.
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Headquarters: Rockville, United States · 91 employees · maxcyte.com